OBJECTIVE: To address mechanisms that control the activity of human peptidyl arginine deiminase type 4 (PAD-4). METHODS: PAD-4 autocitrullination was determined by anti-modified citrulline immunoblotting, using purified recombinant and endogenous PAD-4 from activated human primary neutrophils and cell lines expressing PAD-4. The citrullination sites in PAD-4 were determined by mass spectrometry. Mechanisms of autocitrullination-induced inactivation and the functional consequences of autocitrullination in PAD-4 polymorphic variants were addressed using purified components and cell lines expressing PAD-4 wild-type, PAD-4 mutant, and PAD-4 polymorphic variants relevant to rheumatoid arthritis (RA). RESULTS: PAD-4 is autocitrullinated in vitro and during activation of primary cells and cell lines expressing PAD-4. Interestingly, this modification inactivated the function of the enzyme. The efficiency of inactivation differed among genetically defined PAD-4 variants relevant to RA. PAD-4 was citrullinated at 10 sites, which are clustered into 3 distinct regions, including a cluster of arginines around the active site cleft where Arg-372 and -374 were identified as the potential autocitrullination targets that inactivate the enzyme. Autocitrullination also modified the structure of PAD-4, abrogating its recognition by multiple rabbit antibodies, but augmenting its recognition by human anti-PAD-4 autoantibodies. CONCLUSION: Our findings suggest that autocitrullination regulates the production of citrullinated proteins during cell activation, and that this is affected by structural polymorphisms in PAD-4. Autocitrullination also influences PAD-4 structure and immune response.
OBJECTIVE: To address mechanisms that control the activity of humanpeptidyl arginine deiminase type 4 (PAD-4). METHODS:PAD-4 autocitrullination was determined by anti-modified citrulline immunoblotting, using purified recombinant and endogenous PAD-4 from activated human primary neutrophils and cell lines expressing PAD-4. The citrullination sites in PAD-4 were determined by mass spectrometry. Mechanisms of autocitrullination-induced inactivation and the functional consequences of autocitrullination in PAD-4 polymorphic variants were addressed using purified components and cell lines expressing PAD-4 wild-type, PAD-4 mutant, and PAD-4 polymorphic variants relevant to rheumatoid arthritis (RA). RESULTS:PAD-4 is autocitrullinated in vitro and during activation of primary cells and cell lines expressing PAD-4. Interestingly, this modification inactivated the function of the enzyme. The efficiency of inactivation differed among genetically defined PAD-4 variants relevant to RA. PAD-4 was citrullinated at 10 sites, which are clustered into 3 distinct regions, including a cluster of arginines around the active site cleft where Arg-372 and -374 were identified as the potential autocitrullination targets that inactivate the enzyme. Autocitrullination also modified the structure of PAD-4, abrogating its recognition by multiple rabbit antibodies, but augmenting its recognition by human anti-PAD-4 autoantibodies. CONCLUSION: Our findings suggest that autocitrullination regulates the production of citrullinated proteins during cell activation, and that this is affected by structural polymorphisms in PAD-4. Autocitrullination also influences PAD-4 structure and immune response.
Authors: G A Schellekens; B A de Jong; F H van den Hoogen; L B van de Putte; W J van Venrooij Journal: J Clin Invest Date: 1998-01-01 Impact factor: 14.808
Authors: Graeme L Cuthbert; Sylvain Daujat; Andrew W Snowden; Hediye Erdjument-Bromage; Teruki Hagiwara; Michiyuki Yamada; Robert Schneider; Philip D Gregory; Paul Tempst; Andrew J Bannister; Tony Kouzarides Journal: Cell Date: 2004-09-03 Impact factor: 41.582
Authors: Yanming Wang; Joanna Wysocka; Joyce Sayegh; Young-Ho Lee; Julie R Perlin; Lauriebeth Leonelli; Lakshmi S Sonbuchner; Charles H McDonald; Richard G Cook; Yali Dou; Robert G Roeder; Steven Clarke; Michael R Stallcup; C David Allis; Scott A Coonrod Journal: Science Date: 2004-09-02 Impact factor: 47.728
Authors: Violeta Romero; Justyna Fert-Bober; Peter A Nigrovic; Erika Darrah; Uzma J Haque; David M Lee; Jennifer van Eyk; Antony Rosen; Felipe Andrade Journal: Sci Transl Med Date: 2013-10-30 Impact factor: 17.956
Authors: Duc T Tran; Valerie J Cavett; Vuong Q Dang; Héctor L Torres; Brian M Paegel Journal: Proc Natl Acad Sci U S A Date: 2016-12-08 Impact factor: 11.205
Authors: Mandar Bawadekar; Daeun Shim; Chad J Johnson; Thomas F Warner; Ryan Rebernick; Dres Damgaard; Claus H Nielsen; Ger J M Pruijn; Jeniel E Nett; Miriam A Shelef Journal: J Autoimmun Date: 2017-02-07 Impact factor: 7.094